Clinical Trials Logo

Short Stature clinical trials

View clinical trials related to Short Stature.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04219007 Active, not recruiting - Short Stature Clinical Trials

Vosoritide for Selected Genetic Causes of Short Stature

Start date: August 4, 2020
Phase: Phase 2
Study type: Interventional

Short stature can be caused by a number of genetic etiologies, many of which directly affect the growth plate. The FGFR3/CNP pathway is central to growth of the chondrocyte. The study team hypothesizes that patients with selected genetic causes of short stature that interact with this pathway will benefit from treatment with vosoritide, a CNP analog, a selective NPR-B agonist which directly targets the growth plate. This study will enroll patients with short stature in selected genetic categories and will follow them for a 6 month observation period to obtain a baseline growth velocity, safety profile and quality of life assessment. Patients will then be treated with vosoritide for 12 months and will be assessed for safety monitoring and improvement in height outcomes.